ArticleJournal for immunotherapy of cancer2020

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.

Jared E Lopes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.